Background The validation of intermediate markers as surrogate markers (S) for the true outcome of interest (T) in clinical trials offers the possibility for trials to be run more quickly and cheaply by using the surrogate endpoint in place of the true endpoint. Purpose Working within a principal stratification framework, we propose causal quantities to evaluate surrogacy using a Gaussian copula model for an ordinal surrogate and time-to-event final outcome. The methods are applied to data from four colorectal cancer clinical trials, where S is tumor response and T is overall survival. Methods For the Gaussian copula model, a Bayesian estimation strategy is used and, as some parameters are not identifiable from the data, we explore the use of informative priors that are consistent with reasonable assumptions in the surrogate marker setting to aid in estimation. Results While there is some bias in the estimation of the surrogacy quantities of interest, the estimation procedure does reasonably well at distinguishing between poor and good surrogate markers. Limitations Some of the parameters of the proposed model are not identifiable from the data, and therefore, assumptions must be made in order to aid in their estimation. Conclusions The proposed quantities can be used in combination to provide evidence about the validity of S as a surrogate marker for T.
Introduction
There is much interest in the use of intermediate outcome variables as surrogate endpoints (S) for the true outcome of interest (T) in randomized clinical trials, as they may allow trials to be run more quickly and inexpensively by basing the evaluation of the treatment effect on the earlier measured surrogate. Many previous methods of surrogate validation rely on models for the conditional distribution of T given the treatment (Z) and S. However, S is a post-randomization variable, and unobserved, simultaneous predictors of S and T may exist. When such confounders exist, these methods will not have a causal interpretation. Therefore, there has been much recent work in the area of surrogacy assessment under the principal surrogacy 1 approach, which looks at the distribution of the potential outcomes of T conditional on principal strata based on the potential outcomes of S, which are pre-randomization variables. [2] [3] [4] Treatment effect estimates that condition on these principal strata are therefore causal estimates. In this article, using the principal surrogacy framework, we describe surrogate validation measures for multivariate normal surrogate and outcome data, with extensions to non-normally distributed data through the use of a Gaussian copula model.
We consider the entire joint distribution of the potential outcomes of S and the potential outcomes of T, denoted by S(Z) and T(Z) for Z = 0,1. We first consider the scenario where both S(Z) and T(Z) are continuous and their joint distribution is multivariate normal. 5 We then relax the multivariate normality assumption and consider the scenario of an ordinal categorical surrogate marker and a censored time-toevent true outcome. 6 Once parameter estimates from the joint distribution of (S(0), S(1), T(0), T(1)) are obtained, we examine various causal quantities that may aid in the assessment of S as a surrogate marker for T. As only two of the four potential outcomes are observed for each subject ((S(0), T(0)) for those in the control arm and (S(1), T(1)) for those in the treatment arm), the models are not fully identifiable from the data. We therefore use a Bayesian estimation strategy and propose some prior distributions that are consistent with reasonable assumptions in the surrogacy setting to aid in estimation. We apply the method to data from an advanced colorectal cancer clinical trial where tumor response is assessed as a surrogate for overall survival.
Measures of surrogacy
In the setting of multivariate normal surrogate and outcome variables, we previously developed a model 5 for the joint distribution of the potential outcomes of S and T, given by
We focus on the conditional distribution of [T(0),T(1)jS(0),S(1)] and derive quantities from this distribution to determine surrogacy. Specifically, we can consider E(T(1) 2 T(0)jS(1) 2 S(0) = s), which is linear in s and equal to g 0 + g 1 s, where
The value of g 0 is then a measure of the ''associative effect,'' 1 which should be near zero for a valid surrogate, indicating that the average treatment effect on T is near zero when there is no treatment effect on S, and g 1 is a measure of the ''dissociative effect'' which should be non-zero for a valid surrogate, indicating that there is an expected treatment effect on T when there is a treatment effect on S. We can also consider the entire curve of E(T(1) 2 T(0)jS(1) 2 S(0) = s), 3 which provides estimates of the expected treatment effect within principal strata of S that may be clinically interesting. For a good surrogate, the curve should pass through the origin, be monotonic and be much different from zero at large values of jsj.
In the setting of an ordinal categorical S, and a timeto-event T, a Gaussian copula model is used to model the joint distribution of the two potential outcomes for each of S and T. 6 We assume that S(0) and S(1) arise from latent underlying standard normal Gaussian random variables, denoted byS(0) andS (1), respectively, such that
. We denote the marginal cumulative distributions ofS(0),S(1), T(0), and T(1) by FS (0) , FS (1) , F T (0) , and F T (1) , respectively, and assume that their joint cumulative distribution is generated by the Gaussian copula function:
))jGg, whereỹ = (S(0), S(1), T (0), T (1)) and F P is the standard P-variate normal distribution, with correlation matrix
In this setting, we can again consider measures of the associative and dissociative effect which can be measured by E(log(T(1)/T(0))jS(1) 2 S(0) = s). This conditional expectation provides an estimate of the dissociative effect when s = 0 and a measure of the associative effect at each value of s when s 6 ¼ 0. We can also consider the entire curve of E(log(T(1)/ T(0))jS(1) 2 S(0) = s) versus s.
Estimation
In both the multivariate normal model and the Gaussian copula model, there are four correlation parameters that are unidentifiable from the observed data (r s , r t , r 10 , and r 01 ). Therefore, a Bayesian approach was developed 5, 6 with reasonable priors in the surrogate evaluation setting used to aid in estimation. Unobserved potential outcomes are treated as missing data and imputed from the appropriate posterior distribution at each iteration of the Markov chain. Monte Carlo extraction method Non-informative priors are placed on the parameters that define the mean and variance in the multivariate normal model, and on l T Z , g T Z , and the a k Z 's in the Gaussian copula model, all of which are fully identified parameters. Marginal priors are placed on each of the correlation parameters of the covariance matrix, and the use of different prior assumptions is explored. For each of these, there is the additional assumption that the correlation matrix must be positive definite. The priors considered for the correlation parameters include the following:
1. Jointly uniform prior such that for each of the six correlations p(r) ; Uni f(21, 1); 2. Jointly uniform prior such that for each of the six correlations p(r) ; Uni f(0,1); 3. Uniform over the region where all rs ! 0, r 01 \ min(r 00 , r 11 , r s , r t ) and r 10 \ min(r 00 , r 11 , r s , r t ); 4. Beta priors such that p(r 11 ) ; Uni f(0,1); p(r 00 ) ; Uni f(0,1); p(r 10 ) and p(r 01 ) ; Beta(3a 0 , 3 2 3a 0 ) such that P(r 01 , r 10 min(r 00 ,r 11 )) = 0:80; p(r s ) and p(r t ) ; Beta(3a 0 , 3 2 3a 1 ) such that P(r s , r t ! E½r 10 ) = 0:80.
wherer 00 andr 11 are the Pearson correlation coefficients when S and T are normally distributed, and the polyserial correlation coefficients when S is ordinal and T is a time-to-event. These are estimable from the observed data. E[r 10 ] is the expected value under the Beta(3a 0 , 3 À 3a 0 ) distribution. In simulation studies, 5, 6 we found that prior 4 performed the best in terms of bias and mean squared error for both the multivariate normal model and the Gaussian copula model.
Applications
To illustrate the use of the Gaussian copula model, we consider the use of the ordinal variable ''tumor response'' as a surrogate for overall survival in advanced colorectal cancer. Tumor response and overall survival are common endpoints of interest in cancer clinical trials, and there is a large literature on the use of tumor response as a surrogate marker for overall survival. [7] [8] [9] We apply our estimation method to data from four separate meta-analyses in advanced colorectal cancer. 10 Each of the four studies is a combination of separate randomized trials. Study 1 consists of eight trials that compare fluoropyrimidines given as a bolus intravenous injection (5-fluorouracil (5FU) bolus) to 5FU modulated by methotrexate with a total of 1168 subjects, 11 Study 2 consists of four trials that compare 5FU bolus to hepatic arterial infusion of 5FU with a total of 244 patients, 12 Study 3 consists of nine trials that compare 5FU bolus to 5FU modulated by leucovorin with a total of 1378 patients, 13 and Study 4 consists of six trials that compare 5FU bolus to 5FU given in continuous infusion with a total of 1216 patients. 14 Within each study, we pool the data from the separate trials. The results from fitting the Gaussian copula model to Study 4 have been previously presented. 6 The inclusion of these additional studies allows an assessment of whether the causal surrogacy quantity, E(log(T(1)/T(0))jS(1),S(0)) is similar across different treatment comparisons.
Patients in each trial were followed with tumor response and survival time recorded. Tumor response was defined by one of four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). In our analysis, the true endpoint T is survival time, defined as the time from randomization to death from any cause, and the surrogate endpoint S is tumor response, defined as a categorical variable with S = 1, 2, 3, 4 for PD, SD, PR, and CR, respectively. The binary treatment indicator for treatment Z is set to 0 for control treatment and 1 for experimental treatment. Tumor response was measured after approximately 3-6 months of follow-up in advance of the recorded survival time.
There are modest effects of the treatment on S and T in the four studies. The odds ratio for response (PR or CR) in the treatment versus control arm was 2.05 (95% credible interval (CI): Figure 1(a) and (b) provide a plots of E[log(T(1)/T(0))jS(1) 2 S(0) = s] versus S(1) 2 S(0) = s for each of the four studies using prior 1 and using prior 4, respectively. Figure 2 provides plots of E[log(T(1)/T(0))jS(1) 2 S(0) = s] versus S(1) 2 S(0) = s with the 95% CI for the curve for each of the four studies using prior d.
Under both prior 1 and prior 4, Figure 1 shows that E[log(T(1)/T(0))jS(1) 2 S(0) = 0] is approximately 0 for all four studies, indicative of a good principal surrogate, with E[log(T(1)/T(0))jS(1) 2 S(0) = s] increasing in s. We would therefore conclude that tumor response appears to be a moderately good principal surrogate for overall survival, and the fact that the four estimated curves are quite similar suggests that this is a quantity that may generalize from one treatment comparison to the next. Figure 2 shows that there is very little uncertainty around S(1) 2 S(0) = 0; however, the CIs become much larger at either end of the curve when S(1) 2 S(0) = 23 and S(1) 2 S(0) = 3. Table 1 1)] is similar across studies, then it may be possible to use this information to predict treatment effects on overall survival in a future trial based only on the surrogate outcome if there is a way to predict the missing counterfacutal values of S, such as by using baseline covariate information.
Discussion
We have developed methods for surrogacy assessment within the principal stratification framework when the joint distribution of the potential outcomes of S and T is multivariate normal, with an extension to nonnormally distributed data through the use of a Gaussian copula model. Our simulation results 5, 6 suggest that the estimation procedure is able to distinguish valid principal surrogates from invalid ones. As some parameters of the proposed model are not identifiable from the data, certain assumptions must be made in order to aid in their estimation. A Bayesian estimation strategy is used, which allows the use of context specific prior distributions on the unidentified parameters to be explored. The priors that were placed on the unidentified parameters seem reasonable in the setting that we are considering. The use of other priors or other context specific assumptions about unidentified parameters or the conditional relationships between the potential outcomes could be made to accommodate the specific setting of the trial of interest. 4 
